Last reviewed · How we verify
Ethinyl Estradiol + Cyproterone acetate
Ethinyl estradiol suppresses gonadotropins while cyproterone acetate blocks androgen receptors, reducing androgenic effects in women.
Ethinyl estradiol suppresses gonadotropins while cyproterone acetate blocks androgen receptors, reducing androgenic effects in women. Used for Contraception, Acne vulgaris in women, Hirsutism.
At a glance
| Generic name | Ethinyl Estradiol + Cyproterone acetate |
|---|---|
| Sponsor | Fundação Educacional Serra dos Órgãos |
| Drug class | Combined oral contraceptive with anti-androgenic activity |
| Target | Androgen receptor (cyproterone acetate); estrogen receptor (ethinyl estradiol); gonadotropin suppression |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Gynecology |
| Phase | FDA-approved |
Mechanism of action
Ethinyl estradiol is a synthetic estrogen that inhibits FSH and LH secretion, suppressing ovulation and endogenous hormone production. Cyproterone acetate is a progestin with anti-androgenic properties that competitively blocks androgen receptors at target tissues. Together, they reduce circulating androgens and androgen-mediated effects, making this combination effective for conditions driven by excess androgens.
Approved indications
- Contraception
- Acne vulgaris in women
- Hirsutism
- Androgenetic alopecia in women
- Polycystic ovary syndrome (PCOS)
Common side effects
- Nausea
- Breast tenderness
- Headache
- Breakthrough bleeding
- Venous thromboembolism
- Hypertension
Key clinical trials
- Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) (NA)
- GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (PHASE2, PHASE3)
- The Progression From Dysmenorrhoea to Chronic Pelvic Pain
- "Effect of CPA/EE Drug on Periodontal Tissue and hsCRP Levels in PCOS Patients With Gingivitis
- Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa (PHASE3)
- Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety (NA)
- Phlebotomy and Polycystic Ovary Syndrome (NA)
- The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: